Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 146 No. 2728 (2016)

Unlocking the molecular mechanisms of antipsychotics – a new frontier for discovery

  • Heather Bowling
  • Emanuela Santini
DOI
https://doi.org/10.4414/smw.2016.14314
Cite this as:
Swiss Med Wkly. 2016;146:w14314
Published
03.07.2016

Summary

Despite the use of antipsychotics to treat schizophrenia for the last several decades, little was understood about their molecular mechanisms of action. In this review, we discuss recent studies that have helped elucidate mechanisms of action of antipsychotics and their potential interplay with genetic, metabolomic, proteomic, and other cellular process-related discoveries in schizophrenia pathology. We also highlight genes that have been identified in multiple studies in both schizophrenia patients and in antipsychotic action that are related to glucose and cellular metabolism, the cytoskeleton, protein synthesis, cell adhesion and synaptic activity. Though some questions of antipsychotic mechanisms of action, such as primary versus off-target effects, remain, the recent gains in understanding how to treat schizophrenia at the molecular level are promising. We propose that these recent insights provide a new and more complete landscape for drug discovery and patient biomarker development.

References

  1. van Rossum JM. The significance of dopaminereceptor blockade for the action of neuroleptic drugs. Archives Internationales de Pharmacodynamie et de Therapie 1966;160:492–4.
  2. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192(4238):481–3.
  3. Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry. 1976;133(2):197–202.
  4. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993:50(2):85–94.
  5. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
  6. The Use of Medicines in the United States: Review of 2011. IMS Institute for Healthcare Informatics. 2012
  7. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophr Bull. 2006;32(2):234–7.
  8. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225–33.
  9. Marchese G, Casti P, Ruiu S, Saba P, Sanna A, Casu G, Pani L. Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. Br J Pharmacol. 2003;140(3):520–6.
  10. http://medical-dictionary.thefreedictionary.com/catalepsy
  11. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry. 2008;192(3):161–3.
  12. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–96.
  13. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59(2):69–75.
  14. Marder SR1, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2-3):123–36.
  15. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006:2(4):427–43.
  16. McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry. 2006;189:433–40. Replaced Boettger
  17. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4–15.
  18. Roche Media Release April 14, 2014.
  19. Alberati D, Moreau JL, Lengyel J, Hauser N, Mory R, Borroni E, et al. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology. 2012;62(2):1152–61.
  20. “Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results” Eli Lilly Media Release. August 29, 2012.
  21. Valjent E, Bertran-Gonzalez J, Bowling H, Lopez S, Santini E, Matamales M, et al. Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32. Neuropsychopharmacology. 2011;36(12):2561–70.
  22. Borgkvist A, Fisone G. Psychoactive drugs and regulation of the cAMP/PKA/DARPP-32 cascade in striatal medium spiny neurons. Neurosci Biobehav Rev. 2007;31(1):79–88.
  23. Blasi G, Napolitano F, Ursini G, Taurisano P, Romano R, Caforio G, et al. DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia. Proc Natl Acad Sci U S A. 2011;108(3):1158–63.
  24. Håkansson K, Galdi S, Hendrick J, Snyder G, Greengard P, Fisone G. Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J Neurochem. 2006;96(2):482–8.
  25. Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB, Fisone G. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci U S A. 2000;15;97(4):1856–60.
  26. Bertran-Gonzalez J, Håkansson K, Borgkvist A, Irinopoulou T, Brami-Cherrier K, Usiello A, et al. Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons. Neuropsychopharmacology. 2009;34(7):1710–20.
  27. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry. 2008;13(10):918–29.
  28. Beaulieu JM, Del’guidice T, Sotnikova TD, Lemasson M, Gainetdinov RR. Beyond cAMP: The Regulation of Akt and GSK3 by Dopamine Receptors. Front Mol Neurosci. 2011;4:38.
  29. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, Caron MG. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A. 2008;105(36):13656–61.
  30. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A. 2004;101(14):5099–104.
  31. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 2004;36(2):131–7.
  32. Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol. 2007;10(1):7–19.
  33. Pan B, Chen J, Lian J, Huang XF, Deng C. Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats. PLoS One. 2015;10(7):e0132722.
  34. Chan MK, Tsang TM, Harris LW, Guest PC, Holmes E, Bahn S. Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients. Mol Psychiatry. 2011;16(12):1189–202.
  35. Bowling H, Zhang G, Bhattacharya A, Pérez-Cuesta LM, Deinhardt K, Hoeffer CA, Neubert TA, Gan WB, Klann E, Chao MV. Antipsychotics activate mTORC1-dependent translation to enhance neuronal morphological complexity. Sci Signal. 2014;7(308):ra4.
  36. Bonito-Oliva A, Pallottino S, Bertran-Gonzalez J, Girault JA, Valjent E, Fisone G. Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1. Neuropharmacology. 2013;72:197–203.
  37. Weeks KR, Dwyer DS, Aamodt EJ. Antipsychotic drugs activate the C. elegans akt pathway via the DAF-2 insulin/IGF-1 receptor. ACS Chem Neurosci. 2010;1(6):463–73.
  38. Jones CA, Watson DJG, Fone KCF. Animal models of schizophrenia. Br J Pharmacol. 2011;164:1162–94.
  39. Kendler KS, MacLean CJ, O’Neill FA, Burke J, Murphy B, Duke F, et al. Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families. Am J Psychiatry. 1996;153:1534–40.
  40. Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron. 2006;52:179–96.
  41. Stefansson H, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877–92.
  42. Munafò MR, Thiselton DL, Clark TG, Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry. 2006;11:539–46.
  43. Mei L, Xiong W-C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9:437–52.
  44. Sullivan PF, Lin D, Tzeng J-Y, van den Oord E, Perkins D, Stroup TS, et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry. 2008;13:570–84.
  45. Agim ZS, Esendal M, Briollais L, Uyan O, Meschian M, Martinez LAM, et al. Discovery, validation and characterization of Erbb4 and Nrg1 haplotypes using data from three genome-wide association studies of schizophrenia. Hu VW, ed. PLoS ONE 2013;8:e53042.
  46. Rimer M, Barrett DW, Maldonado MA, Vock VM, Gonzalez-Lima F. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport. 2005;16:271–5.
  47. O’Tuathaigh CM, O’Sullivan GJ, Kinsella A, Harvey RP, Tighe O, Croke DT, Waddington JL. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport. 2006;17:79–83.
  48. Karl T, Duffy L, Scimone A, Harvey RP, Schofield PR. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav. 2007;6:677–87.
  49. Dean B, Karl T, Pavey G, Boer S, Duffy L, Scarr E. Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophr Res. 2008;99:341–9.
  50. Deakin IH, Law AJ, Oliver PL, Schwab MH, Nave KA, Harrison PJ, Bannerman DM. Behavioural characterization of neuregulin 1 type I overexpressing transgenic mice. Neuroreport. 2009;20:1523–8.
  51. Deakin IH, Nissen W, Law AJ, Lane T, Kanso R, Schwab MH, et al. Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation. Cereb Cortex. 2012;22:1520–9.
  52. Roy K, Murtie JC, El-Khodor BF, Edgar N, Sardi SP, Hooks BM, et al. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci USA. 2007;104:8131–6.
  53. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000;9:1415–23.
  54. Hennah W, Varilo T, Kestilä M, Paunio T, Arajärvi R, Haukka J, et al. Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. Hum Mol Genet. 2003;12:3151–9.
  55. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA. 2005;102:8627–32.
  56. Cannon TD, Hennah W, van Erp TGM, Thompson PM, Lonnqvist J, Huttunen M, et al. Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch Gen Psychiatry. 2005;62:1205–13.
  57. Koike H, Arguello PA, Kvajo M, Karayiorgou M, Gogos JA. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc Natl Acad Sci USA. 2006;103:3693–7.
  58. Kuroda K, et al. Behavioral alterations associated with targeted disruption of exons 2 and 3 of the Disc1 gene in the mouse. Hum Mol Genet. 2011;20:4666–83.
  59. Pletnikov MV, Ayhan Y, Nikolskaia O, Xu Y, Ovanesov MV, Huang H, et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry. 2008;13:173–86–115.
  60. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA. 2007;104:14501–6.
  61. Li W, Zhou Y, Jentsch JD, Brown RAM, Tian X, Ehninger D, et al. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci. 2007;104:18280–5.
  62. Duan X, Chang JH, Ge S, Faulkner RL, Kim JY, Kitabatake Y, et al. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell. 2007;130:1146–58.
  63. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301–8.
  64. Mouri A, Noda Y, Enomoto T, Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int. 2007;51(2-4):173–84.
  65. Hoffman DC, Donovan H, Cassella JV. The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology (Berl). 1993;111(3):339–44.
  66. Abdul-Monim Z, Reynolds GP, Neill JC. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res. 2006;169(2):263–73.
  67. Steinpreis RE, Anders KA, Branda EM, Kruschel CK. The effects of atypical antipsychotics and phencyclidine (PCP) on rotorod performance. Pharmacol Biochem Behav. 1999;63(3):387–94.
  68. Profaci CP, Krolikowski KA, Olszewski RT, Neale JH. Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. Psychopharmacology (Berl). 2011;216(2):235–43.
  69. Schlumberger C, Schäfer D, Barberi C, Morè L, Nagel J, Pietraszek M, et al. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol. 20(1):56–66.
  70. Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, et al. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-​benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Eur J Pharmacol. 2012;685(1-3):59–69.
  71. Liu Y, Guo L, Duan H, Zhang L, Jiang N, Zhen X, Shen J. Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors. RSC Adv. 2015;5:40964–77.
  72. Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci. 2001;26(5):395–410.
  73. McKinney WT, Moran EC. Animal models of schizophrenia. Am J Psychiatry. 1981;138(4):478–83.
  74. Rebec GV, Bashore TR. Critical issues in assessing the behavioral effects of amphetamine. Neurosci Biobehav Rev. 1984;8(1):153–9.
  75. Andersen MP, Pouzet B. Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats. Psychopharmacology (Berl). 2001;156(2-3):291–304.
  76. Weiner I, Lubow RE, Feldon J. Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology (Berl). 1984;83(2):194–9.
  77. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary.Institute of Medicine (US) Forum on Neuroscience and Nervous System Disorders. Washington (DC): National Academies Press (US); 2013.
  78. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005;162:939–46 CrossRefMedlineWeb of ScienceGoogle Scholar
  79. Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: Antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry. 2003;48:716–21.
  80. Chiba S, Hashimoto R, Hattori S, Yohda M, Lipska B, Weinberger DR, Kunugi H. Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus. J Neural Transm (Vienna). 2006;113(9):1337–46.
  81. Ahmed EU, Ahmed S, Ukai W, Matsumoto I, Kemp A, McGregor IS, Kashem MA. Antipsychotic induced alteration of growth and proteome of rat neural stem cells. Neurochem Res. 2012;37(8):1649–59.
  82. Ma D, Chan MK, Lockstone HE, Pietsch SR, Jones DN, Cilia J, et al. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res. 2009;8(7):3284–97.
  83. Ji B, Zhang Z, Zhang M, Zhu H, Zhou K, Yang J, et al. Differential expression profiling of the synaptosome proteome in a rat model of antipsychotic resistance. Brain Res. 2009;1295:170–8.
  84. Kumarasinghe N, Beveridge NJ, Gardiner E, Scott RJ, Yasawardene S, Perera A, et al. Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication. Int J Neuropsychopharmacol. 2013;16(7):1483–503.
  85. Mas S, Gassó P, Boloc D, Rodriguez N, Marmol F, Sanchez J, et al. Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms. Pharmacogenomics J. 2015: in press (a).
  86. Thomas EA, George RC, Danielson PE, Nelson PA, Warren AJ, Lo D, Sutcliffe JG. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol Psychiatry. 2003;8(12):983–93.
  87. Korostynski M, Piechota M, Dzbek J, Mlynarski W, Szklarczyk K, Ziolkowska B, Przewlocki R. Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs. BMC Genomics. 2013;14:606.
  88. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 2012;485(7396):109–13.
  89. Law AJ, Hutchinson LJ, Burnet PW, Harrison PJ. Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex. J Neurosci Res. 2004;76(3):376–82.
  90. Rosenfeld M, Brenner-Lavie H, Ari SG, Kavushansky A, Ben-Shachar D. Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol Psychiatry. 2011;69(10):980–8.
  91. Engmann O, Hortobágyi T, Pidsley R, Troakes C, Bernstein HG, Kreutz MR, et al. Schizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition. Brain. 2011;134(Pt 8):2408–21.
  92. Burbaeva GSh, Boksha IS, Turishcheva MS, Vorobyeva EA, Savushkina OK, Tereshkina EB. Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4):675–80.
  93. Spanaki C, Zaganas I, Kounoupa Z, Plaitakis A. The complex regulation of human glud1 and glud2 glutamate dehydrogenases and its implications in nerve tissue biology. Neurochem Int. 2012;61(4):470–81.
  94. Brennand K, Savas JN, Kim Y, Tran N, Simone A, Hashimoto-Torii K, et al. Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia. Mol Psychiatry. 2015;20(3):361–8.
  95. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9(7):684–97.
  96. English JA, Pennington K, Dunn MJ, Cotter DR. The neuroproteomics of schizophrenia. Biol Psychiatry. 2011;69(2):163–72.
  97. Schwab SG, Hoefgen B, Hanses C, Hassenbach MB, Albus M, Lerer B, et al. Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol Psychiatry. 2005;58(6):446–50.
  98. Bajestan SN, Sabouri AH, Nakamura M, Takashima H, Keikhaee MR, Behdani F, et al. Association of AKT1 haplotype with the risk of schizophrenia in Iranian population. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(4):383–6.
  99. Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshita Y, et al. Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry. 2004;56(9):698–700.
  100. Xu MQ1, Xing QH, Zheng YL, Li S, Gao JJ, He G, et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry. 2007;68(9):1358–67.
  101. Thiselton DL1, Vladimirov VI, Kuo PH, McClay J, Wormley B, Fanous A, et al. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry. 2008;63(5):449–57.
  102. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000;9(9):1415–23.
  103. Kim JY, Duan X, Liu CY, Jang MH, Guo JU, Pow-anpongkul N, et al. DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron. 2009;63(6):761–73.
  104. Mas S, Gassó P, Ritter MA, Malagelada C, Bernardo M, Lafuente A. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway. Eur Neuropsychopharmacol. 2015;25(1):51–9 b.
  105. English JA, Fan Y, Föcking M, Lopez LM, Hryniewiecka M, Wynne K, et al. Reduced protein synthesis in schizophrenia patient-derived olfactory cells. Transl Psychiatry. 2015;5:e663.
  106. Chen J, Wang M, Waheed Khan RA, He K, Wang Q, et al. The GSK3B gene confers risk for both major depressive disorder and schizophrenia in the Han Chinese population. J Affect Disord. 2015;185:149–55.
  107. Shelton MA, Newman JT, Gu H, Sampson AR, Fish KN, MacDonald ML, Moyer CE, DiBitetto JV, Dorph-Petersen KA, Penzes P, Lewis DA, Sweet RA. Loss of Microtubule-Associated Protein 2 Immunoreactivity Linked to Dendritic Spine Loss in Schizophrenia. Biol Psychiatry. 2015;78(6):374–85.
  108. Rosoklija G, Keilp JG, Toomayan G, Mancevski B, Haroutunian V, Liu D, et al. Altered subicular MAP2 immunoreactivity in schizophrenia. Prilozi. 2005;26(2):13–34.
  109. Jones LB, Johnson N, Byne W. Alterations in MAP2 immunocytochemistry in areas 9 and 32 of schizophrenic prefrontal cortex. Psychiatry Res. 2002;114(3):137–48.
  110. Arnold SE, Lee VM, Gur RE, Trojanowski JQ. Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. Proc Natl Acad Sci U S A. 1991;88(23):10850–4.
  111. Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry. 2006;11(5):459–70, 423.
  112. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM, et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry. 2008;13(12):1102–17.
  113. Hook V, Brennand KJ, Kim Y, Toneff T, Funkelstein L, Lee KC, Ziegler M, Gage FH. Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons. Stem Cell Reports. 2014: 3(4):531-8.
  114. Tam GW, van de Lagemaat LN, Redon R, Strathdee KE, Croning MD, Malloy MP, et al. Confirmed rare copy number variants implicate novel genes in schizophrenia. Biochem Soc Trans. 2010;38(2):445–51.
  115. Yu GI, Kim SK, Park HJ, Kim JW, Chung JH, Shin DH. The C allele of synonymous SNP (rs1142636, Asn170Asn) in SYN1 is a risk factor for the susceptibility of Korean female schizophrenia. Synapse. 2012;66(11):979–83.
  116. Goes FS, McGrath J, Avramopoulos D, Wolyniec P, Pirooznia M, Ruczinski I, et al. Genome-wide association study of schizophrenia in Ashkenazi Jews. Am J Med Genet B Neuropsychiatr Genet. 2015: in press.
  117. Pak C, Danko T, Zhang Y, Aoto J, Anderson G, Maxeiner S, et al. Human Neuropsychiatric Disease Modeling using Conditional Deletion Reveals Synaptic Transmission Defects Caused by Heterozygous Mutations in NRXN1. Cell Stem Cell. 2015;17(3):316–28.
  118. Todarello G, Feng N, Kolachana BS, Li C, Vakkalanka R, Bertolino A, et al. Incomplete penetrance of NRXN1 deletions in families with schizophrenia. Schizophr Res. 2014;155(1-3):1–7.
  119. Atz ME, Rollins B, Vawter MP. NCAM1 association study of bipolar disorder and schizophrenia: polymorphisms and alternatively spliced isoforms lead to similarities and differences. Psychiatr Genet. 2007;17(2):55–67.
  120. Tanaka Y, Yoshida S, Shimada Y, Ueda H, Asai K. Alteration in serum neural cell adhesion molecule in patients of schizophrenia. Hum Psychopharmacol. 2007;22(2):97–102.
  121. Vawter MP, Usen N, Thatcher L, Ladenheim B, Zhang P, VanderPutten DM, et al. Characterization of human cleaved N-CAM and association with schizophrenia. Exp Neurol. 2001;172(1):29–46.
  122. Poltorak M, Wright R, Hemperly JJ, Torrey EF, Issa F, Wyatt RJ, Freed WJ. Monozygotic twins discordant for schizophrenia are discordant for N-CAM and L1 in CSF. Brain Res. 1997;751(1):152–4.
  123. Sullivan PF, Keefe RS, Lange LA, Lange EM, Stroup TS, Lieberman J, Maness PF. NCAM1 and neurocognition in schizophrenia. Biol Psychiatry. 2007;61(7):902–10.
  124. Ayalew M, Le-Niculescu H, Levey DF, Jain N, Changala B, Patel SD, et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry. 2012;17(9):887–905.
  125. Dolgin E. Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014;13(9):641–2.
  126. Mas S, Gassó P, Parellada E, Bernardo M, Lafuente A. Network analysis of gene expression in peripheral blood identifies mTOR and NF-κB pathways involved in antipsychotic-induced extrapyramidal symptoms. Pharmacogenomics J. 2015;15(5):452–60 c.
  127. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem. 2007;282(19):14056–64.
  128. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 2011;3(3):192–222. (replaces Costa-mattioli)
  129. Moses V. Chao, Eric Klann, and Annalisa M. VanHook. A conversation about a Research Article published in the 14 January 2014 issue of Science Signaling. Podcast Science Signaling. 2014: http://stke.sciencemag.org/content/suppl/2014/01/10/7.308.pc2.DC1.
  130. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl). 1995;120(2):128–33.
  131. Adams MR, Brandon EP, Chartoff EH, Idzerda RL, Dorsa DM, McKnight GS. Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. Proc Natl Acad Sci U S A. 1997;94(22):12157–61.
  132. Atkins JB, Chlan-Fourney J, Nye HE, Hiroi N, Carlezon WA Jr, Nestler EJ. Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs. Synapse. 1999;33(2):118–28.
  133. MacGibbon GA, Lawlor PA, Bravo R, Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Brain Res Mol Brain Res. 1994;23(1-2):21–32.
  134. Bateup HS, Santini E, Shen W, Birnbaum S, Valjent E, Surmeier DJ, et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A. 2010;107(33):14845–50.
  135. Fink-Jensen A, Schmidt LS, Dencker D, Schülein C, Wess J, Wörtwein G, Woldbye DP. Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor. Eur J Pharmacol. 2011;656(1-3):39–44.
  136. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry. 2000;176:249–52.
  137. Leucht S, Heres S, Hamann J, Kane JM. Methodological issues in current antipsychotic drug trials. Schizophr Bull. 2008;34(2):275–85.